Bachelor's degree in Pharmacy-Biochemistry
Bachelor's Degree
Status | Complete |
---|---|
Part Time | No |
Years | 2004 - 2008 |
Awarding Institution | #1 ORGANISATION NOT LISTED |
Bachelor's degree in Pharmacy-Biochemistry
Bachelor's Degree
Status Complete Part Time No Years 2004 - 2008 Awarding Institution #1 ORGANISATION NOT LISTED
Master’s degree in Biosciences applied to Pharmacy
Master's Degree
Status Complete Part Time No Years 2009 - 2011 Project Title Evaluation of the interaction between Galectin-1 and Zinc and their potential structural and functional implications Project Description Introduction: Galectin-1 (Gal-1) is a multifunctional protein that specifically recognizes glycans with -galactosides through carbohydrate recognition domains (CRD). Gal-1 is a homodimeric protein of 14.900daltons, pI=5.6, shows a jelly-roll molecular topology composed of two anti-parallels - sheet, has no signal peptide and contains 6 cysteines, 7 glutamic acids, 9 aspartic acids and 4 histidines per monomer. This lectin binds to different biological molecules contained in the cell surface, nucleus and extracellular matrix components. Zinc is an important metal in biological systems because can participate in the maintenance of protein structure and biological activity. Usually, cysteine , histidine, glutamic acid and aspartic acid residues are preferential targets for interaction with Zn. Approximately 10% of the human proteome is potentially capable to forming complexes with Zn. The Zn2+ ion exhibits properties suitable for both catalytic and structural protein functions. Proteins zinc binding sites can be divided into catalytic, structural, co-catalytic and protein interface sites.There are reports in the literature that shows the interaction between galectin-1 and organic ions. However, were not found reports about Zn-Gal-1 complexes. Objective: The aim of this study was to evaluate the existence and implications of the interaction between galectin-1 and Zn2+ ion. Materials and Methods: Human recombinant Gal-1 (monomer and dimmer) was obtained and purified. Also, the conditions for the use of Gal-1 were standardized. The interaction Zn/Gal-1 was assessed by biophysical an biological procedures. The analysis in vitro and in silico was made by spectrofluorimetry, circular dichroism, precipitation test, method of GRID, and molecular dynamics. The in vitro analysis of biological parameters were performed by hemmaglutination and laminin binding (ELISA) tests. Results and Discussion: The addition of ZnCl2 in Gal-1 solution causes increased fluorescence emission of tryptophan-70 and a red shift, alters the circular dichroism spectrum and causes precipitation of Gal-1 protein. These events occurred in a selective manner dependent of Zinc concentration. The in silico analysis indicates that the probable site of Zn/Gal-1 complexation is distinct from the CRD and is formed by the amino acids Glu-15, Asp-92 and Asp-134, assuming trigonal bipyramidal conformation and with coordination number equal to 5 . Conclusion: The biophysical in vitro and in silico findings suggests that Galectin-1 has the ability to complex with the Zn2+ ion. Awarding Institution #1 ORGANISATION NOT LISTED
Ph.D. degree in Medical Sciences
Doctor of Philosophy
Status Complete Part Time No Years 2011 - 2015 Project Title Genetic profile analysis of tumour stem cells in locally advanced breast cancer Project Description INTRODUCTION: Breast cancer is the most common cancer in women worldwide and metastatic dissemination is the principal factor related to death by this disease. Breast cancer stem cells (bCSC), defined in this work as the ALDH1high/LIN-/ESA+ population, are thought to be responsible for metastasis and chemoresistance. The objective of this work is to find gene master regulators, in particular transcription factors (TFs), which are controlling the bCSC phenotype. METHODS: We used in this work two groups of datasets with transcriptome data, the discovery dataset group contains one dataset obtained by ourselves containing three paired samples comparing the bCSC and the bulk of the tumor (My Data - bCSC/Bulk dataset), a dataset with eight paired samples comparing the bCSC and cancer cells (Wicha - bCSC/CC dataset) and a dataset with 115 samples of breast cancer tissue (clinical response dataset). The second group, validation datasets, contains the BRCA-TCGA dataset with information of 621 samples, 4142 breast cancer samples of the Kmplot tool, 17 primary samples of BasL subtype and their information of grafting in patient derived xenografts and analyzes of cell lines (MF10A and HMLE). For the analyzes we used the paired t-test in the Limma R package, the ARACNE algorithm for the inference of regulons in the clinical response dataset, MRA-FET to define the master regulators of the bCSC phenotype, and GSEA to identify the biological meaning of the findings in the different datasets. RESULTS: We identified 12 TFs as master regulators of the bCSC phenotype, with nine of them forming two highly interconnected networks, one positively related with the bCSC phenotype formed by SNAI2, TWIST, PRRX1, BNC2 and TBX5 with its regulons, defined here as the mesenchymal transcription network and one negative correlated to the phenotype formed by SCML4, ZNF831, SP140 and IKZF3, defined as the immune response transcription network, totally unknown in the context of breast cancer in the literature. Although still with weak evidence, ZEB1 seems to control the two networks and can be responsible for the expression of ALDH1 and of the three remaining TFs: ID4, HOXA5 and TEAD1. As their names portray, our data showed in the different datasets, and independently of the molecular subtype and of the platform used, that the mesenchymal transcription network seems to be responsible for the bCSC phenotype and the immune response transcription network to the adaptive immune response in the tumor and a better prognosis for the patients. We also defined 10 membrane proteins as new markers and/or therapeutic targets of the bCSC. CONCLUSION: We found and described two TF networks that seem to control the bCSC phenotype, one of them totally unknown until now and correlated to a good prognosis. Our findings have a clear potential for clinical use. Awarding Institution #1 ORGANISATION NOT LISTED
About USIR
Administrator e-mail: library-research@salford.ac.uk
This application uses the following open-source libraries:
Apache License Version 2.0 (http://www.apache.org/licenses/)
Apache License Version 2.0 (http://www.apache.org/licenses/)
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search